the keynote-024 precedent for advanced-nsclc treatment
Published 5 years ago • 358 plays • Length 3:31Download video MP4
Download video MP3
Similar videos
-
1:48
results of keynote-024 trial of pembrolizumab in nsclc
-
1:18
dr. reck on the safety of pembrolizumab in keynote-024 in metastatic nsclc
-
1:02
pembrolizumab monotherapy for nsclc: keynote-024 update
-
4:57
keynote-024 shows prolonged nsclc survival benefit with pembrolizumab | julie brahmer
-
1:20
pembro continues to demonstrate os benefit in first-line nsclc: keynote-024 update
-
3:04
keynote-024 update: pembrolizumab vs platinum-based chemotherapy in nsclc
-
5:00
implications for pembrolizumab in nsclc
-
0:30
copy of dr. camidge on the keynote-024 trial in nsclc
-
2:44
pembrolizumab and chemotherapy in advanced nsclc
-
8:44
upfront immunotherapy for pd-l1 nsclc
-
2:30
dr. lopes on the keynote-042 results of frontline pembrolizumab in nsclc
-
4:47
benefit of pembrolizumab in nsclc: the keynote trials
-
3:13
latest data from keynote 42: pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit...
-
1:13
a new standard of care for advanced lung cancer: what’s next for pembrolizumab?
-
3:10
pembrolizumab new option for firstline treatment of advanced lung cancer with high pdl-1 expression
-
1:27
dr. camidge on the keynote-024 trial in nsclc
-
1:23
i-o monotherapy for advanced nsclc
-
3:12
post-immunotherapy & frontline treatments for advanced nsclc
-
3:47
pembrolizumab as treatment for oligometastatic nsclc